TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01630694

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 3D Laser Scanning of the Head
Description: Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Measurements and Digital Photo's of the head, neck and Mouth
Description: Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Exam of the Tongue
Description: The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Laser Scanning of the Head
Description: Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurements and Digital Photo's of the head, neck and Mouth
Description: Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Exam of the Tongue
Description: The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
Study: NCT04222361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI
Description: Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
Study: NCT04512131

Intervention type: PROCEDURE
Intervention: dialysis mode
Description: intermittent hemodialysis or continuous renal replacement therapy

Intervention type: PROCEDURE
Intervention: dialysis mode
Description: intermittent hemodialysis or continuous renal replacement therapy
Study: NCT02019303

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNA and Core biopsy
Description: Both procedures will be performed on the same lymph node
Study: NCT03534128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the effect of cues on virtual spatial navigation using a virtual district
Description: Evaluation of the effect of cues on virtual spatial navigation using a virtual district
Study: NCT04973787

Intervention type: BIOLOGICAL
Intervention: biological disease-modifying antirheumatic drugs (bDMARDs)
Description: bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA
Study: NCT01603680

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow
Description: Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
Study: NCT03184038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Undergo assessment of neurocognitive function

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT01603680

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non circumferential spread in ultrasound-guided median and ulnar nerves block
Description: Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
Study: NCT03184038

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01865175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ionic iron
Description: Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ionic iron
Description: Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
Study: NCT02908139

Intervention type: DEVICE
Intervention: BR-102 plus PWA
Description: Monitoring of Arterial Stiffness and Central Aortic Pressure

Intervention type: DEVICE
Intervention: Tanita MC780 MA S
Description: The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
Study: NCT01865175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme iron polypeptide
Description: Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heme iron polypeptide
Description: Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
Study: NCT04136743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
Study: NCT04461444

Intervention type: GENETIC
Group type: OTHER
Intervention: Skin biopsy
Description: COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~* risk of pain due to the procedure performed under local anaesthesia~* can leave a visible scar (about 2 x 1 cm)
Study: NCT01636323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
Study: NCT03664362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BSHAPE Intervention
Description: The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
Study: NCT03892252

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04744493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExaBlate 4000
Description: The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
Study: NCT02158988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.
Study: NCT02209870

Intervention type: BEHAVIORAL
Intervention: E-checklist Group
Description: The patient group after E-checklist system deployed
Study: NCT01511094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goniocurettage
Description: Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
Study: NCT03109483

Intervention type: OTHER
Group type: OTHER
Intervention: Geriatric Activation Program Pellenberg
Description: intensive multicomponent physical therapy week program
Study: NCT00809796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentamidine
Description: one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
Study: NCT01968421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85 BV
Description: two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OM-85 BV
Description: two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
Study: NCT02959801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical thrombectomy
Description: Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
Study: NCT00624091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Description: Cardiac surgery within 48 hours of randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: State-to-the-art treatment
Description: Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
Study: NCT03052894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydraulic Monitoring Device
Description: The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard EMG Monitoring Device
Description: Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator.
Study: NCT02292576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa Pure
Description: Cocoa Pure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa Pure
Description: Cocoa Pure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo.
Study: NCT03012269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Study: NCT02901223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard quadrantectomy
Description: standard conservative surgery with no use of any plastic techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oncoplastic breast surgery
Description: Integration of plastic techniques with oncological procedures
Study: NCT00515853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Biofeedback sessions or biofeedback exercises
Study: NCT03103490

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FSPG
Description: Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
Study: NCT03856385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking
Description: Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
Study: NCT04870229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02813876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocol
Study: NCT04554017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education/Training
Description: It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
Study: NCT02919930

Intervention type: DEVICE
Group type: OTHER
Intervention: Switch from oronasal to nasal mask during ASV treatment
Description: One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.

Intervention type: DEVICE
Group type: OTHER
Intervention: Switch from nasal to oronasal mask during ASV treatment
Description: One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
Study: NCT01395888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)
Description: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: • Tiotropium (18 mcg) administered QD via a HandiHaler
Study: NCT03278860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: an identical amount of placebo nasal spray will be applied to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: an identical amount of placebo nasal spray will be applied to each subject.
Study: NCT02136082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asha Support + Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asha Support + Food

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asha Support + Training + Food

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asha Support Only
Study: NCT02651597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study: NCT02323178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
Study: NCT02230098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Study: NCT01860378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full price
Description: Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full price
Description: Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: $5 off
Description: Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $5 off
Description: Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
Study: NCT02204501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 5mg Syrup
Description: All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~* On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~* On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 5mg Syrup
Description: All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~* On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~* On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 264 mg BID
Description: Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
Study: NCT03559634

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
Study: NCT02982707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Single oral dose
Study: NCT04175717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy-led follow-up programme
Description: In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.